Maurelli Martina, Gisondi Paolo, Bellinato Francesco, Mantovani Alessandro, Targher Giovanni, Girolomoni Giampiero
Section of Dermatology and Venereology, University of Verona, 37129 Verona, Italy.
Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona, 37129 Verona, Italy.
J Clin Med. 2023 Sep 19;12(18):6057. doi: 10.3390/jcm12186057.
There are no published studies on the prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with atopic dermatitis (AD).
To estimate the prevalence of NAFLD (assessed via liver ultrasonography) in adults with moderate-to-severe AD.
We performed a retrospective, cross-sectional, observational study including adult patients affected by moderate-to-severe AD, moderate-to-severe chronic plaque psoriasis, or a previous diagnosis of thin melanoma in situ (considered as the control group) who attended the Verona University Hospital between January 2022 and April 2023. Fatty liver was assessed via liver ultrasonography.
A total of 144 adults with AD, 466 with chronic plaque psoriasis, and 99 with thin melanoma were included. The prevalence rates of ultrasound-detected NAFLD among patients with in situ melanoma, those with moderate-to-severe AD, and those with moderate-to-severe chronic plaque psoriasis were 23.2% (23 out of 99), 24.1% (36 out of 144), and 49.8% (228 out of 466), respectively ( < 0.01). Logistic regression analysis revealed that being of male sex, a higher age, a higher body mass index, and psoriasis were independently associated with NAFLD, whereas AD was not.
Our findings show that the prevalence of ultrasound-detected NAFLD in patients with moderate-to-severe AD was comparable to that of patients with a previous diagnosis of in situ melanoma. It is plausible to hypothesize that the Th2-type inflammation typically characterizing AD is not a risk factor for NAFLD. Patients with moderate-to-severe psoriasis, but not those with AD, should be screened for NAFLD and other metabolic comorbidities.
目前尚无关于特应性皮炎(AD)患者中非酒精性脂肪性肝病(NAFLD)患病率的已发表研究。
评估中度至重度AD成年患者中NAFLD(通过肝脏超声检查评估)的患病率。
我们进行了一项回顾性、横断面观察性研究,纳入了2022年1月至2023年4月期间在维罗纳大学医院就诊的中度至重度AD成年患者、中度至重度慢性斑块状银屑病患者或既往原位薄黑色素瘤诊断患者(作为对照组)。通过肝脏超声检查评估脂肪肝情况。
共纳入144例AD成年患者、466例慢性斑块状银屑病患者和99例原位薄黑色素瘤患者。原位黑色素瘤患者、中度至重度AD患者和中度至重度慢性斑块状银屑病患者中超声检测到的NAFLD患病率分别为23.2%(99例中的23例)、24.1%(144例中的36例)和49.8%(466例中的228例)(<0.01)。逻辑回归分析显示,男性、年龄较大、体重指数较高和银屑病与NAFLD独立相关,而AD则无关。
我们的研究结果表明,中度至重度AD患者中超声检测到的NAFLD患病率与既往原位黑色素瘤诊断患者相当。可以推测,AD典型的Th2型炎症不是NAFLD的危险因素。中度至重度银屑病患者而非AD患者应筛查NAFLD和其他代谢合并症。